The U.S. Court of Appeals for the Federal Circuit has upheld the Patent Trial and Appeal Board’s invalidation of next-generation DNA sequencing patents that Columbia University is asserting against Illumina Inc.
Columbia says technology its researchers developed is driving “blockbuster commercial success” at San Diego-based Illumina, but the Federal Circuit agreed with the PTAB that the three patents at issue were obvious or anticipated based on older patents and scientific research dating back to the 1980s.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
